MSD, the developing company of simbastatin, will sell atorvastatin from the next month
MSD will launch the atorvastatin and ezetimibe hyperlipidemia complex ‘Atozet’ within the middle of the next month.
Atozet has been approved in 23 January 2015 and secured the base of the launch with the approval of the insurance benefit in 2 months after the approval.
Thus, followed by the lau...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
